GW311616 hydrochloride GW311616A|cas:197890-44-1|西域试剂

GW311616 hydrochloride GW311616A,98.71%

产品编号：Bellancom-15891A| CAS NO：197890-44-1| 分子式：C₁₉H₃₂ClN₃O₄S| 分子量：433.99

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-15891A		￥5500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

GW311616 hydrochloride GW311616A

产品介绍

GW-311616 是高活性，口服生物相容性，长效的人中性白细胞弹性蛋白酶 (HNE) 抑制剂，IC₅₀ 为 22 nM，K_i 为 0.31 nM。

生物活性

GW-311616 is a potent, orally bioavailable, long duration and selective human neutrophil elastase (HNE) inhibitor with IC₅₀ value of 22 nM and K_i value of 0.31 nM.

体外研究

GW-311616 (150 μM; 48 hours) markedly suppresses NE activity in U937 and K562 cells lines.
GW311616A (20-320 μM; 48 hours; U937 cells) treatment inhibits proliferation and induces apoptosis in leukemia cells.
GW-311616 (150 μM; U937 cells) treatment can increase the protein expression levels of Bax and decrease the expression of Bcl-2.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	U937 and K562 cells
Concentration:	150 μM
Incubation Time:	48 hours
Result:	Markedly suppressed NE activity.

Apoptosis Analysis

Cell Line:	U937 cells
Concentration:	20 μM, 40 μM, 80 μM, 160 μM, 320 μM
Incubation Time:	48 hours
Result:	The rate of apoptosis was enhanced.

Western Blot Analysis

Cell Line:	U937 cells
Concentration:	150 μM
Incubation Time:	48 hours
Result:	Increased the protein expression levels of Bax and decreased the expression of Bcl-2.

体内研究
(In Vivo)

GW-311616 (2 mg/kg; oral administration) rapidly abolishes the circulation of neutrophil elastase (NE) in dogs, while >90% inhibition is maintained for 4 days. This prolonged effect is independent to be due to penetration of neutrophils in bone marrow by orally administrated GW-311616. GW-311616 has moderate terminal elimination half-life (t_1/2) of 1.1 hours and 1.5 hours for dog (2 mg/kg, oral), rat (2 mg/kg, oral), respectively.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Dogs (9-month-old)
Dosage:	0.22 mg/kg, 0.66 mg/kg and 2 mg/kg (Pharmacokinetic study)
Administration:	Oral administration
Result:	At 0.22 mg/kg, greater than 50% inhibition of elastase is achieved 6 hours after dosing, with activity returning towards control values. Single oral dose of 2 mg/kg rapidly abolishes circulating enzyme activity, and greater than 90% inhibition is maintained for 4 days.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Dogs (9-month-old)
Dosage:	0.22 mg/kg, 0.66 mg/kg and 2 mg/kg (Pharmacokinetic study)
Administration:	Oral administration
Result:	At 0.22 mg/kg, greater than 50% inhibition of elastase is achieved 6 hours after dosing, with activity returning towards control values. Single oral dose of 2 mg/kg rapidly abolishes circulating enzyme activity, and greater than 90% inhibition is maintained for 4 days.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Dogs (9-month-old)
Dosage:	0.22 mg/kg, 0.66 mg/kg and 2 mg/kg (Pharmacokinetic study)
Administration:	Oral administration
Result:	At 0.22 mg/kg, greater than 50% inhibition of elastase is achieved 6 hours after dosing, with activity returning towards control values. Single oral dose of 2 mg/kg rapidly abolishes circulating enzyme activity, and greater than 90% inhibition is maintained for 4 days.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (230.42 mM; Need ultrasonic)

H₂O : 100 mg/mL (230.42 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.3042 mL	11.5210 mL	23.0420 mL
5 mM	0.4608 mL	2.3042 mL	4.6084 mL
10 mM	0.2304 mL	1.1521 mL	2.3042 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (5.76 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.76 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (5.76 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.76 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.76 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.76 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。